The Peptide-Based Vaccines Research Group was established in 2021 with the support of the MTA’s Momentum Programme. The peptides, peptide derivatives and conjugates produced in the group are used in various research areas. New formulation strategies are being developed to enhance the biological activity of synthetic peptides and to maintain their stability. Using colloidal chemistry systems, we develop peptide delivery platforms with several advantageous properties such as target delivery, programmed drug release and enhanced immunogenicity.